Business Wire | Oct 12, 2021 12:25PM EDT

FLEXION THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Flexion Therapeutics, Inc. - FLXN

Oct. 12, 2021

NEW ORLEANS--(BUSINESS WIRE)--Oct. 12, 2021--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC ("KSF") are investigating the proposed sale of Flexion Therapeutics, Inc. (NasdaqGM: FLXN) to Pacira BioSciences, Inc. (NasdaqGS: PCRX). Under the terms of the proposed transaction, shareholders of Flexion will receive only $8.50 in cash and one non-tradable contingent value right (CVR) worth up to $8.00 per share in cash (assuming certain conditions are met) for each share of Flexion that they own. KSF is seeking to determine whether this consideration and the process that led to it are adequate, or whether the consideration undervalues the Company.

If you believe that this transaction undervalues the Company and/or if you would like to discuss your legal rights regarding the proposed sale, you may, without obligation or cost to you, e-mail or call KSF Managing Partner Lewis S. Kahn (lewis.kahn@ksfcounsel.com) toll free at any time at 855-768-1857, or visit https://www.ksfcounsel.com/cases/nasdaqgm-flxn/ to learn more.

Please note that the merger is structured as a tender offer, such that time may be of the essence.

To learn more about KSF, whose partners include the Former Louisiana Attorney General, visit www.ksfcounsel.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20211012005961/en/

CONTACT: Kahn Swick & Foti, LLC Lewis S. Kahn, Managing Partner lewis.kahn@ksfcounsel.com 855-768-1857